|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
TRANSPLANTATION
From the Division of Hematology, III Department of
Medicine, University Medical School Mainz, Germany; and Institute of
Pathology, University of Cologne, Germany.
Depletion of T lymphocytes from allogeneic bone marrow transplants
successfully prevents the development of graft-versus-host disease
(GvHD) but is associated with impaired engraftment, immunosuppression, and abrogation of the graft-versus-leukemia effect. We therefore explored the possibility of selectively eliminating alloreactive T
cells by CD95/CD95L-mediated activation-induced cell death (AICD) in a
major histocompatibility complex allogeneic murine model system.
Activation of resting or preactivated T lymphocytes from C3H/HeJ
(H-2k) mice was induced with irradiated BALB/cJ
(H-2d) mouse-derived stimulators. Substantial decrease
( Graft-versus-host disease (GvHD) represents
a major complication of allogeneic bone marrow transplantation (BMT),
which results in significant morbidity and mortality. Donor T
lymphocytes present in the BM or peripheral blood stem cell transplant
cause GvHD by recognizing major as well as minor histocompatibility
antigens (reviewed by Ferrara et al1). Although innovative
strategies for the prediction, prevention, or treatment of this caveat
in allogeneic BMT have been proposed,2-9 prophylaxis or
treatment of GvHD still remains unsatisfactory. Removal of
donor-derived T lymphocytes prior to transplantation efficiently
ameliorates GvHD. However, ex vivo depletion of T cells has been
associated with an increased risk of viral opportunistic
infections,10 impaired engraftment,11 and the
loss of the graft-versus-leukemia (GvL) effect, resulting in an
increased incidence of recurrence of leukemia.12,13 These
observations emphasize the clinical importance of allogeneic T cells in
conferring a protective antiviral immunity as well as mediating a GvL
effect. Several clinical and experimental studies support the idea that
GvHD and GvL are not only mediated by the same (host-specific) T cell
but also by distinct (leukemia-specific) alloreactive donor T-cell
populations.14-16 Moreover, allo-major histocompatibility
complex (MHC)-restricted cytotoxic T lymphocytes (CTLs) to antigens
frequently expressed at elevated levels on leukemic cells can be cloned
from an allorestricted T-cell repertoire and used to mediate a GvL
reaction without causing GvHD.17-19 However, immunotherapy
with ex vivo-generated specific T cells requires the identification
and characterization of tumor-specific antigens to be targeted. To
circumvent this prerequisite of cloning leukemia-specific T cells, we
aimed to develop a complementing strategy that would allow ex vivo
elimination of alloreactive T cells responsible for GvHD while
preserving an allorestricted T-cell population able to both mediate GvL
and antiviral immunity effects. Because the activation-induced cell
death (AICD) mediated by CD95/CD95 ligand (CD95L) (reviewed by Lenardo
et al20) represents an important physiologic pathway to
control the expansion of antigen-activated T cells at the down phase of
an immune response, it therefore might provide a means to selectively
deplete activated alloreactive T lymphocytes. Induction of AICD
triggered by repetitive T-cell receptor (TCR) re-engagement in the
presence of interleukin-2 requires antigen-specific activation of the T
cell and appears not to affect bystander T cells.21-23
Thus, inducing AICD in alloreactive T lymphocytes by repetitive
stimulation with alloantigen ex vivo prior to transfer should allow us
to leave T cells unaffected that confer antiviral or GvL effects.
In this study we tested this approach by the induction of apoptosis in
activated alloreactive T lymphocytes in an allogeneic mixed lymphocyte
culture (MLC) using an agonistic monoclonal antibody (mAb) to CD95
followed by transfer of residual allogeneic T cells in a lethal P to
F1(P The results presented suggest that elimination of alloreactive donor T
lymphocytes following activation by CD95 death receptor-mediated depletion might provide one approach to modify the T-cell repertoire in
allogeneic transplants and complement strategies to include pathogen-specific T lymphocytes and in vitro-generated tumor-specific T cells for immunotherapy in an allogeneic BMT.
Mice and tumor cell lines
The animals were housed in sterilized microisolator cages with filter
tops, and experimental procedures were performed according to German
federal and state regulations and the National Institutes of Health
Guide for the Care and Use of Laboratory Animals.
The age of mice to be used for experiments ranged from 8 to 14 weeks.
For adoptive transfer experiments, only female F1 mice were
taken as recipients.
The A20 tumor cell line represents a B-cell lymphoma derived from
BALB/c mice. The thymoma cell line EL-4 was derived from C57BL/6
(H-2b) mice.
Media and reagents
Biotin-conjugated antibodies to H-2d and H-2k, fluorescein isothiocyanate (FITC)-labeled anti-CD3 and anti-CD4 antibodies, phycoerythrin-conjugated anti-CD8 antibody, and appropriate isotype controls were purchased from BD Biosciences (San Diego, CA). FITC- and phycoerythrin-labeled streptavidin was from Jackson ImmunoResearch (West Grove, PA). MicroBeads used for immunomagnetic separation of T cells were from Miltenyi (Bergisch Gladbach, Germany). The anti CD3 (145-2C11) mAb and the anti-CD95 antibody (Jo2) were obtained in a low endotoxin and culture grade from BD Biosciences; isotype-matched hamster immunoglobulin (Ig) and polyclonal goat anti-hamster Ig were purchased from Serotec (Oxford, United Kingdom). Protein G used for cross-linking of Jo2 mAb was from Sigma (Deisenhofen, Germany). The ovalbumin (OVA) peptide (amino acids 323-339 from chicken ovalbumin) was obtained from the Department of Immunohematology, Leiden University Medical Center, The Netherlands. Induction of AICD in MLC assays Single-cell suspensions from spleen or a mixture of spleen and lymph node cells derived from inguinal, axillary, and submandibullary lymph nodes were prepared in complete DMEM followed by red cell lysis using NH4Cl treatment. Purification of CD90+, CD4+, or CD8+ responder T cells from C3H/HeJ or BALB/cJ mice was carried out using a magnetic cell separation system (MACS) according to the manufacturer's instructions (Miltenyi). Cells were incubated with either anti-CD90-, anti-CD4-, or anti-CD8-conjugated MicroBeads in MACS buffer (phosphate-buffered saline [PBS] containing 0.5% FCS) for 20 minutes at 4°C. After removal of excess beads by washing, the cell suspension was passed through a prewashed VS+ separation column placed in a magnetic field, and cells coated with MicroBeads were selected to be transferred into MLC medium. Preparations of T cells were periodically stained with anti-CD90, anti-CD4, or anti-CD8 antibody to be analyzed by flow cytometry. Purity of the enriched T cells always exceeded 95%.Highly purified ex vivo-isolated naive CD4+, CD8+, or CD90+ responder T cells were mixed with irradiated (30 Gy [3000 cGy]) splenic stimulator cells from BALB/c mice (H-2d) or F1 mice (H-2dxk) at concentrations of 1 × 106/mL and 5 × 106/mL, respectively. They were cultured for 5 to 6 days in MLC medium in 96-well round-bottom plates in the absence or presence of various concentrations of soluble agonistic anti-CD95 mAb (Jo2). Depletion of alloreactive T cells for adoptive transfer studies was performed in a bulk culture in 24-well plates generally culturing 2.5 × 106 responder cells with 7.5 × 106 irradiated stimulator cells. To enhance its proapoptotic effect, microtiter plate wells were also coated with anti-hamster Ig at a concentration of 5 µg/mL in PBS prior to addition of anti-CD95 antibody to facilitate cross-linking. Alternatively, protein G was used at 2 µg/mL. In case of a secondary MLC, responder T cells were either prestimulated in vitro with irradiated allogeneic splenic stimulators or immobilized with anti-CD3 antibody in bulk cultures for 3 days or in vivo by intraperitoneal injection of 5 × 106 irradiated BALB/c spleen cells 10 to 14 days prior to isolation. T-cell blasts were then harvested from culture or isolated from spleen and lymph node suspension by immunomagnetic separation using MACS as described above to be restimulated in a bulk culture MLC. When OVA-specific T cells (H-2d) were used to evaluate the specificity of depletion, CD4+ cells were isolated from OVA-TCR transgenic mice by MACS technology as described above and mixed with BALB/c T-cell responder at ratios of 1:1, 1:5, or 1:10 to be cultured with irradiated allogeneic F1 splenic stimulators in the presence of Jo2 mAb. Residual T cells were then not only challenged with F1 cells but also stimulated with these F1 cells in the presence of OVA peptide (0.5 µg/mL). Depending on a primary or secondary MLC or T-cell stimulation by
peptide antigen, 2 or 3 days after beginning the culture the cells
were harvested every day following an overnight pulse with 1 µCi (0.037 MBq) per well of 3H-thymidine. Radioactivity
incorporated into DNA was measured on a Cytolytic assays A total of 2 × 106 A20 (H-2d) or EL-4 (H-2b) tumor cells was labeled with 100 µCi (3.7 MBq) of 51Cr for 4 hours. After washing 3 times in PBS, labeled targets were plated at 1 × 104 cells per well in U-bottom microtiter plates (Nunc, Wiesbaden, Germany). Allogeneic CD90+ responder T cells (H-2k), preactivated in a primary MLC to H-2d spleen cells for 5 days, were washed 3 times and added to triplicate wells at varying effector-target ratios to be incubated for 5 hours. Maximum and spontaneous release were determined by incubation of targets with Triton X-100 (Sigma) or addition of media, respectively. 51Cr activity in the supernatants taken 5 hours later was determined in an auto counter (Packard Instruments, Dreieich, Germany), and lysis was
expressed as a percentage of maximum release.
Experimental model for induction of lethal GvHD Acute and lethal GvHD was induced in a classical P F1 model using C3H/HeJ mice
(H-2K) or BALB/cJ mice
(H-2d) as donor of T cells and (C3H/He × BALB/c)
F1 mice (H-2kxd) as recipients. Following
depletion of alloreactive T cells in bulk culture MLC in the presence
of agonistic anti-CD95 antibody for 5 to 6 days as described above,
remaining T cells were harvested to be purified by immunomagnetic
separation on a MACS column. Single suspensions of highly purified in
vitro-activated viable (trypan blue-excluding) CD4+ or
CD8+ T cells were then injected at various concentrations
through the tail vein into female F1 recipients on
day 0. Mice were sublethally total body
137Cs-irradiated (6.5 Gy [650 cGy]) 4 to 5 hours prior to
adoptive transfer of T cells. Control mice consisted of age- and
sex-matched F1 mice that received syngeneic spleen cells or
untreated allogeneic T cells, respectively.
For BMT studies, BM was obtained aseptically by flushing femurs and tibias of C3H/HeJ donor mice with complete DMEM, and T-cell depletion was carried out by immunomagnetic removal of CD90+ cells using MACS (Miltenyi) as described above. T-cell-depleted BM cells (2 × 107 cells per mouse) were transplanted with highly purified CD4+ or CD8+ donor T cells or T cells depleted of alloreactivity by AICD (2.5 × 106 per animal), respectively, by tail-vein infusion into lethally irradiated F1 recipients on day 0. F1 mice received 13 Gy (1300 cGy) total body irradiation as a split dose (with 3 hours between the 2 doses to reduce gastrointestinal toxicity) 3 to 4 hours prior to BMT. Recipient mice were monitored for clinical signs of GvHD, including diarrhea, alopecia, and hunched posture, and their weight loss was determined. At least 4 recipient mice were included in each experimental group, and adoptive transfer was repeated at least 3 times. Histology of GvHD and immunohistochemistry for CD4 and CD8 antigen expression in tissue-infiltrating lymphocytes Liver, spleen, lymph node, small intestine, kidney, and ear skin sections obtained from mice on various days after adoptive transfer of untreated donor T cells or donor T lymphocytes depleted of alloreactive responders by AICD were either fixed in 10% buffered formalin and embedded in paraffin to be stained with hematoxylin and eosin for microscopic examination or embedded with OCT medium (Tissue-Tek, Zoeterwoude, The Netherlands) to be stored at 80°C for
immunohistochemistry. Slides of cryostat-sliced (5 µm) samples were
first incubated with rat anti-CD8 mAb at 5 µg/mL (BD Biosciences) or
rat anti-CD4 mAb at 2.5 µg/mL (BD Biosciences) overnight at 4°C, followed by rinsing in PBS and incubation with a secondary antibody (0.01 mg/mL biotinylated anti-rat IgG) (Dako, Hamburg, Germany) at room temperature for 30 minutes. The antigen-antibody binding was detected using an avidin-biotin alkaline phosphatase (AP) system (Dako). The slides were immersed briefly in
hematoxylin for counterstaining and evaluated under light microscopy.
Flow cytometry analysis Generally, 1 × 106 viable T cells per sample, isolated from spleen and lymph node preparations by immunomagnetic separation using CD4-, CD8-, or CD90-conjugated MicroBeads (Miltenyi), were incubated for 15 minutes at 4°C with the indicated antibodies. The antibodies were either directly conjugated or biotinylated to be incubated with streptavidin-conjugated FITC or phycoerythrin as second-step reagents, followed by 2 washes (PBS containing 2.5% FCS and 1% sodium azide) between incubations. Viable lymphocytes were gated either by forward and side scatter or on a life gate using 7-aminoactinomycin D (Molecular Probes, Leiden, The Netherlands), and 2-color fluorescence analysis was performed on 10 000 cells using an Epics Altra instrument (Beckman Coulter, Stanford, CA) with Expo 32 software.Statistics All values are expressed as mean ± SD. Statistical analysis of survival data was performed by the Mantel-Cox log-rank test. P < .05 was considered statistically significant.
Proliferative responses of alloreactive T cells are strongly reduced after induction of AICD by agonistic mAb to CD95 Because both CD4+ and CD8+ T cells undergo CD95-mediated activation-induced apoptosis after prolonged activation,20-23 we investigated the possibility of deploying AICD as a method for selective depletion of alloreactive T cells in an allogeneic mixed lymphocyte reaction. Naive T cells isolated ex vivo from C3H/He (H-2k) mice were highly purified into CD4+ or CD8+ T-cell subpopulations by immunomagnetic separation using the MACS technology and cultured together with irradiated unfractionated splenic stimulator cells from BALB/c (H-2d) mice in the presence of increasing concentrations of soluble agonistic mAb (Jo2) to CD95 for 5 to 6 days. Jo2 has previously been shown to induce apoptosis in lymphocytes.25 Following stimulation to the H-2d alloantigen, the proliferative responses of both CD4+ or CD8+ alloreactive T lymphocytes were reduced by up to 90% in the presence of anti-CD95 mAb in a dose-dependent fashion when compared with the proliferation of untreated allogeneic controls (Figure 1). Reduction of proliferative responses was specific for anti-CD95-mediated apoptosis of T cells, because responder cells stimulated in the presence of an anti-CD95 mAb-matched hamster Ig isotype control showed comparable responses to untreated allogeneic controls (Figure 1). Flow cytometry analyses of CD90+ responders isolated at daily time points during stimulation with T-cell-depleted allogeneic stimulators (H-2d) in a 6-day bulk culture by immunomagnetic separation revealed an increased CD95 expression within the first 36 to 48 hours following activation and an increase of apoptotic CD4+ and CD8+ T lymphocytes upon treatment with agonistic anti-CD95 mAb as measured by annexin V and 7-aminoactinomycin D viability staining.
Both naive and preactivated T lymphocytes are equally susceptible to AICD Because T cells have been reported to be initially resistant to AICD upon primary activation but elicit increasing susceptibility to CD95-mediated induction of apoptosis 4 to 5 days20-23 upon sustained TCR re-engagement, we further investigated the induction of AICD on naive versus preactivated T cells.Following polyclonal activation in vitro by TCR cross-linking through
coated anti-CD3 mAb (145-2C11) for 3 days, CD4+ T-cell
blasts as well as freshly isolated resting CD4+ T
lymphocyte mice were stimulated with alloantigen (H-2d) in
a bulk culture MLC in the presence of agonistic mAb to CD95 for 5 days
to be tested for residual response to the stimulating alloantigen in a
mixed lymphocyte reaction. Upon induction of AICD, both primary
stimulated (Figure 2A) or restimulated
(Figure 2B) T-cell responders showed a marked decrease in their
capacity to proliferate to allogeneic splenic stimulators regardless of their preactivation state (note the reduced proliferation of 85% both in Figure 2A and 2B on day 3) in contrast to their untreated responder controls, although with an earlier kinetic in the response to
H-2d for anti-CD3-preactivated cells.
These results suggested that induction of AICD at least in an allogeneic situation upon repetitive stimulation of T lymphocytes with MHC alloantigen was not dependent on the preactivation state of the alloreactive T cells. Induction of AICD in alloreactive T cells is specific for the stimulating alloantigen To evaluate whether alloantigen-specific T-cell depletion by AICD would retain T-cell specificities to defined nonalloantigens, we chose to add I-Ad-restricted OVA323-339-specific CD4+ T cells isolated from BALB/c OVA-TCR transgenic mice24 to allogeneic responder T cells from BALB/c mice (H-2d) at different ratios. These T cells should not be activated in the absence of OVA and thus not be susceptible to AICD. Following culture with splenic stimulators from F1 mice (H-2dxk) in the presence of cross-linked anti-CD95 mAb, remaining responder T cells were then challenged with F1 stimulators as well as with BALB/c-derived spleen cells presenting OVA peptide.As expected from the above findings, restimulation to H-2k
alloantigen in vitro resulted in an impaired proliferative response by
these T cells compared with untreated controls (Figure
3A, in vitro). The proliferation of
untreated T cells to H-2k observed in Figure 3 was truly
allospecific because T cells from the OVA transgenic mice were shown
not to cross-react with H-2kxd (data not shown). In
contrast, proliferation of the responder cells to OVA was preserved in
both anti-CD95-treated and untreated T-cell responder populations
(Figure 3A, in vitro).
In addition, challenge of purified CD4+ and CD8+ T cells isolated ex vivo from F1 recipients 6 days after adoptive transfer of a mixture of OVA-specific T cells and allogeneic T-cell responders of BALB/c donors either left untreated or depleted of alloreactive cells by AICD into irradiated F1 mice confirmed the findings obtained in vitro. Again, the response of pretreated responders to H-2k alloantigen was reduced in contrast to untreated controls (Figure 3B, ex vivo), but stimulation of OVA-specific T cells by OVA peptide-presenting BALB/c spleen cells appeared not to be significantly different (Figure 3B, ex vivo) in both responder populations. These results strongly suggested that induction of AICD using the agonistic mAb Jo2 to CD95 was specific in depleting alloreactive T cells to a given alloantigen while retaining T cells specific for non-MHC antigens like OVA. Abrogation of cytolytic responses of alloreactive T cells after induction of AICD We further tested whether induction of AICD by anti-CD95 mAb would also reduce the cytolytic responses of alloreactive T cells. Following stimulation of purified CD90+ responder T cells from C3H/He mice with irradiated allogeneic splenic stimulators from BALB/c mice in the presence of anti-CD95 mAb (1 µg/mL) in a bulk culture MLC for 5 days, remaining T lymphocytes were recovered from culture after treatment and tested in a cytolytic assay using chromium-labeled A20 cells as targets. The capacity of residual CTLs to kill A20 targets was reduced by at least 80% compared with untreated alloreactive control T cells, which exhibited 50% to 60% specific lysis at an effector-target ratio of 3:1 (Figure 4). This reduction in alloreactive cytoxicity after induction of AICD was again specific for the alloantigen H-2d because there was no significant lysis of EL-4 target cells expressing H-2b (Figure 4). Taken together, these findings and the results presented above strongly suggested that the induction of alloantigen-dependent apoptosis in an activated allogeneic T-cell pool by administration of a CD95 agonistic mAb results in marked depletion of alloreactive T cells to a given alloantigen without grossly affecting T-cell specificities that have not previously been activated in an alloantigen-dependent fashion.
Recipients of allogeneic T cells depleted from host reactivity by AICD do not develop GvHD To verify the efficacy of depleting alloreactive T cells by AICD in vitro, we investigated the potential of residual T cells to evoke a GvHD in the parent C3H/He (H-2k)F1
(BALB/c × C3H/He, H-2dxk) murine GvHD model.
Naive allogeneic CD90+ donor T lymphocytes or
CD90+ T cells primed to H-2d BALB/c spleen
cells in vivo 14 days prior to isolation from donor mice were cultured
with irradiated BALB/c-derived splenic stimulators in bulk MLC in the
presence of Jo2 mAb for 5 to 6 days. Remaining responders were
separated into CD4+ or CD8+ donor T cells by
immunomagnetic separation to be injected into the tail vein of
F1 recipients irradiated (6.5 Gy [650 cGy]) within 6 to 8 hours prior to transfer. During the preparation of T-cell responders,
extensive care was taken to wash out excessive anti-CD95 mAb.
Furthermore, viability and purity of cell preparations was assessed by
flow cytometry as described in "Materials and methods." A dose
response of donor T cells depleted of alloreactivity or left untreated
was performed, and F1 mice that received
1 × 106 to 5 × 106 in vivo-primed and in
vitro-restimulated donor T lymphocytes invariably developed an acute
GvHD between days 9 to 18 after transfer depending on the amount of T
cells injected. GvHD was clinically characterized by rapid weight loss,
severe diarrhea, and hunched posture, and all mice died within 20 days
after T-cell transfer, as shown for injection of
2.5 × 106 T cells per recipient in Figure
5.
Surprisingly, adoptive transfer of donor T lymphocytes depleted of alloreactive donor cells by soluble mAb to CD95 alone also led to the development of lethal GvHD (Figure 5). However, depletion of activated alloreactive T cells using anti-CD95 mAb cross-linked by polyclonal anti-hamster Ig prior to adoptive transfer of purified CD4+ (Figure 5A) or CD8+ (Figure 5B) allogeneic T cells resulted in the amelioration of acute GvHD in F1 recipients. In this experimental group all recipient mice survived and were free of clinical GvHD, as did control mice that received syngeneic spleen cells. Prevention of GvHD was stable and lasted until day 120, when the monitoring was terminated. In recent experiments we also used this P Histopathological examination of sections taken from skin, small
intestine, and spleen at different time points after adoptive transfer
confirmed the survival data: apoptotic cells in the basal layer of
epidermis and inflammation in the cryptic epithelium within the small
intestine due to infiltrating lymphocytes were clearly detectable in
mice injected with unmodified donor T cells, in contrast to
F1 recipients that had received T cells depleted of
alloreactive lymphocytes (Figure 6).
Moreover, immunohistologic staining of spleen showed expansion of
CD4+ T cells and, albeit less extensive, of
CD8+ T cells in F1 mice after transfer of
untreated donor T cells compared with recipients injected with donor T
lymphocytes treated by AICD (Figure 6).
To monitor homing and GvH reactions of alloantigen-activated T cells
after adoptive transfer into F1 hosts, the presence and expansion of adoptively transferred donor T cells in vivo was evaluated. Following immunomagnetic separation of CD90+
cells from single spleen and lymph node cell suspensions of
F1 recipients at various time points after adoptive
transfer, the expansion of H-2k-positive T cells versus
recipient-derived T lymphocytes (H-2kxd) isolated from the
pool of CD90+ cells was analyzed by 2-color flow cytometry
(Figure 7). Proliferation of allogeneic T
cells (H-2k) depleted from alloreactive responders in vitro
by AICD was very low in F1 recipients at day 10 after
initial transfer of 2.5 × 106 cells (Figure 7B; 6.4%
for CD4+ and 4.5% for CD8+, respectively). In
contrast, untreated allogeneic T lymphocytes from C3H/He mice were
significantly expanded (Figure 7A; 33.4% for CD4+ and
22.8% for CD8+, respectively) from the same number of
cells injected.
The significant incidence of GvHD following transfer of donor T lymphocytes contained in the stem cell graft into recipients remains as a major caveat in allogeneic BMT, although various strategies for the prevention have been proposed.2-9 In particular, T-cell depletion is undoubtedly a very efficient method to prevent GvHD; however, it increases the risk of severe infections caused predominantly by Epstein-Barr virus26 and cytomegalovirus,10 engraftment failure,11 and relapse of leukemia.12,13 An ideal strategy for a specific and individualized immunotherapy would thus aim for selective elimination of host-reactive T lymphocytes but would leave all other T-cell specificities recognizing Epstein-Barr virus and cytomegalovirus or leukemia-restricted (minor) histocompatibility antigens and leukemia antigens unaffected. Various experimental means, including elimination of alloreactive T cells by immunotoxin-conjugated mAbs to CD25 mAb (as first described by Datta et al14 and followed by others8) or via the early T cell activation antigen CD69,27 have been employed. Furthermore, suicide gene transfer into donor T lymphocytes,4,5 induction of anergy by blocking costimulatory signals necessary for optimal T-cell activation,6,7 and the administration of cytokines to modify T-cell effector responses9,28 have been reported. These methods, however, affect either primarily T-cell subopulations6,7 or all T cells regardless of their specificity.4,5 They also appear not to be very effective on the negative selection of alloreactive T cells,14 technically quite complex,27 or limited by the development of resistant T lymphocytes transduced with the HSV-Tk suicide gene to ganciclovir.29 Alternatively, the in vitro generation of allorestricted T cells conferring GvL reactivity without causing GvHD has been described.18,19 We explored the possibility of separating alloreactive T cells from antiviral T-cell specificities and possibly GvL-conferring T lymphocytes using the CD95/CD95L-mediated AICD as a strategy to deplete GVH-reactive T lymphocytes by apoptosis. AICD via the CD95 system has been demonstrated to occur in T-cell hybridomas as well as in human and murine T cells following activation by TCR cross-linking or by antigen and is thought to represent an important mechanism to limit the clonal expansion of activated T cells at the down phase of an immune response.20-22,30,31 AICD also plays a major role in the maintenance of peripheral T cell tolerance.20,32 Mature T cells acquire susceptibility to AICD after prolonged activation.20-22 This process requires repetitive TCR re-engagement by antigen or anti-TCR/CD3 complex antibodies, is dependent on cell cycle progression caused by interleukin-2,23,33 and results in apoptosis of antigen-specific T cells but not of resting T cells.20,22,23 Using an (MHC) allogeneic model system we first demonstrated the
requirements for induction of AICD in vitro. Secondly, we used this
physiologic mean to deplete alloreactive T cells from an allogeneic
T-cell repertoire. Upon stimulation of purified naive T lymphocytes
from C3H/He mice with BALB/c mouse-derived allogeneic splenic
stimulators in the presence of an agonistic mAb (Jo2) to CD95 during a
primary MLC proliferation of both CD4+- or
CD8+-alloreactive T cell was substantially ( We then established a classical parent (C3H/HeJ or
BALB/cJ) In line with the results obtained in vitro, we could show by adoptive transfer of donor-derived T lymphocytes that F1 recipients that received allogeneic T cells, depleted from alloreactive responders by AICD in vitro, did not develop a lethal GvHD. In contrast, mice receiving untreated allogeneic T-cell blasts displayed all clinical signs of acute GvHD and died within 20 days after transfer. Recent experiments performed on lethally irradiated F1 mice and receiving BM cells together with pretreated donor T cells also did not yet result in the induction of GvHD compared with controls. Additionally, histopathological examinations of skin and small intestine sections taken from F1 mice with GvHD revealed apoptotic cells in the basal lamina of epidermis and infiltration of lymphocytes into cryptic epithelium of small intestine. The monitoring of allogeneic donor cells in the host by flow cytometry also supported the findings described, because 5-fold expansion of alloreactive T cells was exclusively seen in mice receiving untreated allogeneic T lymphocytes. In contrast, very low host-reactive cells were detected in mice that had received allogeneic cells depleted of alloreactivity. Moreover, splenic cells isolated from F1 recipients 6 days after adoptive transfer of both anti-CD95-pretreated OVA-specific T cells and donor T cells could respond to OVA peptide, whereas proliferation to H-2k was reduced. In summary, these results strongly suggest that depletion of alloreactive T lymphocytes by AICD prevents GvHD and retains functional specificities of non-GVH-reactive donor T cells for engraftment. Although we cannot exclude that a low number of alloreactive T cells might escape induction of AICD because it has been reported that some T cells escape CD95-mediated apoptosis to become memory cells,34 the numbers of remaining alloreactive T cells in our GvHD model appear to be below a clinically relevant threshold. In fact, considering the diverse repertoire of allogeneic T-cell specificities that might confer a GvL effect, it might be conceivable to tolerate a very low number of, for example, defined alloreactive T-cell subpopulations. Because CD4+ T helper 1 (Th-1)-type T cells have been described to be more susceptible to CD95-mediated AICD than their Th-2 type counterparts,35 depletion of alloreactive T cells by AICD also polarizes residual CD4+ GVH-reactive T lymphocytes toward a Th-2 type (data not shown), which additionally might protect against clinical manifestation of acute GvHD.36,37 Moreover, because the CD95/CD95L system has been documented by several groups to play an important role in the pathogenesis of GvHD38,39 and blockade of this pathway appears to ameliorate GvHD without impairing GvL effect,40,41 it remains to be elucidated whether the elimination of alloreactive T lymphocytes by the induction of AICD results in the modifications of allogeneic donor T lymphocytes suitable for preserving a GvL effect in the absence of a clinically manifested GvHD. In conclusion, we have established an (MHC) allogeneic model system
that allows elimination of alloreactive T cells by the induction of
CD95-mediated AICD. Transfer of a modified allogeneic donor
T-lymphocyte repertoire into a P Further studies on the phenotypic and functional characterization of the residual allogeneic T lymphocytes as well as their capacity to confer a GvL effect are in progress. They will help us assess the utility of AICD to optimize clinical BMT.
The authors thank K. Kunz, C. Metz, and S. Khan for expert technical assistance and M. Jülch for the fluorescence-activated cell sorter analysis.
Submitted August 8, 2001; accepted December 6, 2001.
Supported by the research grant "Immunological Tumor Therapy by Allogeneic Stem Cell Transplantation" from the German Cancer Society.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Udo F. Hartwig, III Dept of Medicine, University Medical School Mainz, Langenbeckstr 1, D-55101 Mainz, Germany; e-mail: uhartwig{at}mail.uni-mainz.de.
1. Ferrara JL, Cooke KR, Pan L, Krenger W. The immunopathophysiology of acute graft-versus-host-disease. Stem Cells. 1996;14:473-489[Medline] [Order article via Infotrieve]. 2. Theobald M, Nierle T, Bunjes D, Arnold R, Heimpel H. Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med. 1992;327:1613-1617[Abstract]. 3. Barrett AJ, Mavroudis D, Tisdale J, et al. T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant. 1998;21:543-551[CrossRef][Medline] [Order article via Infotrieve].
4.
Cohen JL, Boyer O, Salomon B, et al.
Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes.
Blood.
1997;89:4636-4645
5.
Bonini C, Ferrari G, Verzeletti S, et al.
HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia.
Science.
1997;276:1719-1723
6.
Guinan EC, Vasiliki AB, Neuberg D, et al.
Transplantation of anergic histoincompatible bone marrow allografts.
N Engl J Med.
1999;340:1704-1714 7. Blazar BR, Taylor PA, Noelle RJ, Vallera DA. CD4+ T cells tolerized ex vivo to host alloantigen by anti-CD40 ligand (CD40L:CD154) antibody lose their graft-versus-host disease lethality capacity but retain nominal antigen responses. J Clin Invest. 1998;102:473-482[Medline] [Order article via Infotrieve].
8.
Montagna D, Yvon E, Calcaterra V, et al.
Depletion of alloreactive T cells by a specific anti-interleukin-2 receptor p55 chain immunotoxin does not impair in vitro antileukemia and antiviral activity.
Blood.
1999;93:3550-3557
9.
Yang YG, Sergio JJ, Pearson DA, Szot GL, Shimizu A, Sykes M.
Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8+ T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
Blood.
1997;90:4651-4660
10.
Li CR, Greenberg PD, Gilbert MJ, et al.
Recovery of HLA-restricted cyto-megalovirus (CMV)-specific T cell responses for allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis.
Blood.
1994;83:1971-1979
11.
Martin PJ.
Donor CD8+ cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.
J Exp Med.
1993;178:703-712 12. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase: increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806-814.
13.
Horowitz MM, Gale RP, Sondel PM, et al.
Graft-versus-leukemia reactions after bone marrow transplantation.
Blood.
1990;75:555-562 14. Datta AR, Barrett AJ, Jiang YZ, et al. Distinct T cell populations distinguish chronic myeloid leukemia cells from lymphocytes in the same individual: a model for separating GVHD from GVL reactions. Bone Marrow Transplant. 1994;14:517-524[Medline] [Order article via Infotrieve].
15.
Jiang YZ, Mavroudis DA, Dermine S, Molldrem J, Hensel NF, Barrett AJ.
Preferential usage of T cell receptor (TCR) V
16.
Falkenburg JHF, Wafelman AR, Joosten P, et al.
Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.
Blood.
1999;94:1201-1208
17.
Molldrem J, Dermine S, Parker K, et al.
Targeted T cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells.
Blood.
1996;88:2450-2457
18.
Gao L, Yang T-H, Tourdot S, Sadovnikova E, Hasserjian R, Stauss HJ.
Allo-major histocompatibility complex-restricted cytotoxic T lymphocytes engraft in bone marrow transplant recipients without causing graft-versus-host disease.
Blood.
1999;94:2999-3006
19.
Gao L, Bellantuono I, Elsässer A, et al.
Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT-1.
Blood.
2000;95:2198-2203
20.
Lenardo M, Chan KM, Hornung F, et al.
Mature T lymphocyte apoptosis
21.
Klas C, Debatin KM, Jonker R, Krammer PH.
Activation interferes with the APO-1 pathway in mature human T cells.
Int Immunol.
1993;5:625-630
22.
Russell JH, White CL, Loh DY, Meleedy-Rey P.
Receptor-stimulated death pathway is opened by antigen in mature T cells.
Proc Natl Acad Sci U S A.
1991;88:2151-2155
23.
Lenardo MJ.
Interleukin-2 programs mouse
24.
Murphy KM, Heimberger AB, Loh DY.
Induction by antigen of intrathymic apoptosis of CD4+ CD8+ TCRlo thymocytes in vivo.
Science.
1990;250:1720-1723 25. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806-809[CrossRef][Medline] [Order article via Infotrieve].
26.
Zutter MM, Martin PJ, Sale GE, et al.
Epstein-Barr virus lymphoproliferation after bone marrow transplantation.
Blood.
1988;72:520-529 27. Koh MBC, Prentice HG, Lowdell MW. Selective removal of alloreactive cells from haematopoetic stem cell grafts: graft engineering for GVHD prophylaxis. Bone Marrow Transplant. 1999;23:1071-1079[CrossRef][Medline] [Order article via Infotrieve]. 28. Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest. 1998;102:115-123[Medline] [Order article via Infotrieve].
29.
Garin MI, Garrett E, Tiberghien P, et al.
Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidin kinase gene.
Blood.
2001;97:122-129 30. Brunner T, Mogli RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T cell hybridomas. Nature. 1995;373:441-444[CrossRef][Medline] [Order article via Infotrieve]. 31. Dhein J, Walczak H, Bäumler C, Debatin K-M, Krammer P. Autorine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 1995;373:438-441[CrossRef][Medline] [Order article via Infotrieve]. 32. Van Parijs L, Ibraghimov A, Abbas A-K. The roles of costimulation and Fas in T cell apoptosis and peripheral tolerance. Immunity. 1996;4:321-329[CrossRef][Medline] [Order article via Infotrieve]. 33. Lissy NA, Van Dyk LF, Becker-Hapak M, Vocero-Akbani A, Mendler JH, Dowdy SF. TCR antigen-induced cell death occurs from a late G1 phase cell cycle check point. Immunity. 1998;8:57-65[CrossRef][Medline] [Order article via Infotrieve].
34.
Kirchhoff S, Müller WW, Krueger A, Schmitz I, Krammer PH.
TCR-mediated up-regulation of cFLIPshort correlates with resistance toward CD95-mediated apoptosis by blocking death-inducing signalling complex activity.
J Immunol.
2000;165:6293-6300
35.
Zhang X, Brunner T, Carter L, et al.
Unequal death in T helper cell (Th)1 and Th2 effectors: Th1, but not Th2, effectors undergo rapid Fas/FasL-mediated apoptosis.
J Exp Med.
1997;185:1837-1849
36.
Fowler DH, Kurasawa K, Smith R, Eckhaus M-A, Gress R-E.
Donor CD4-enriched cells of TH2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice.
Blood.
1994;84:3540-3549 37. Krenger W, Snyder KM, Byon JCH, Falzarano G, Ferrara JLM. Polarized type 2 alloreactive CD4+ and CD8+ donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol. 1995;155:585-593[Abstract]. 38. Via CS, Nguyen P, Shustov A, Drappa J, Elkon KB. A major role for the Fas pathway in acute graft-versus-host disease. J Immunol. 1996;157:5387-5393[Abstract].
39.
Baker MB, Riley RL, Podack ER, Levy RB.
Graft-versus-host-disease-associated lymphoid hypoplasia and B cell dysfunction is dependent upon T cell-mediated Fas-ligand function, but not perforin function.
Proc Natl Acad Sci U S A.
1997;94:1366-1371
40.
Tsukada N, Kobata T, Aizawa Y, Yagita H, Okumura K.
Graft-versus-leukemia effect and graft-versus-host disease can be differentiated by cytotoxic mechanisms in a murine model of allogeneic bone marrow transplantation.
Blood.
1999;93:2738-2747
41.
Schmaltz C, Alpdogan O, Horndasch KJ, et al.
Differential use of Fas ligand and perforin cytotoxic pathways by donor T cells in graft-versus-host disease and graft-versus-leukemia effect.
Blood.
2001;97:2886-2895
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  O. Bohana-Kashtan, S. Morisot, R. Hildreth, C. Brayton, H. I. Levitsky, and C. I. Civin Selective Reduction of Graft-versus-Host Disease-Mediating Human T Cells by Ex Vivo Treatment with Soluble Fas Ligand J. Immunol., July 1, 2009; 183(1): 696 - 705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Mielke, R. Nunes, K. Rezvani, V. S. Fellowes, A. Venne, S. R. Solomon, Y. Fan, E. Gostick, D. A. Price, C. Scotto, et al. A clinical-scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique Blood, April 15, 2008; 111(8): 4392 - 4402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mielke, K. Rezvani, B. N. Savani, R. Nunes, A. S. M. Yong, J. Schindler, R. Kurlander, V. Ghetie, E. J. Read, S. R. Solomon, et al. Reconstitution of FOXP3+ regulatory T cells (Tregs) after CD25-depleted allotransplantion in elderly patients and association with acute graft-versus-host disease Blood, September 1, 2007; 110(5): 1689 - 1697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. C. Wehler, M. Nonn, B. Brandt, C. M. Britten, M. Grone, M. Todorova, I. Link, S. A. Khan, R. G. Meyer, C. Huber, et al. Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines Blood, January 1, 2007; 109(1): 365 - 373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Solomon, S. Mielke, B. N. Savani, A. Montero, L. Wisch, R. Childs, N. Hensel, J. Schindler, V. Ghetie, S. F. Leitman, et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation Blood, August 1, 2005; 106(3): 1123 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Watson, G. Y. Zhang, M. Sartor, and S. I. Alexander "Pruning" of Alloreactive CD4+ T Cells Using 5- (and 6-)Carboxyfluorescein Diacetate Succinimidyl Ester Prolongs Skin Allograft Survival J. Immunol., December 1, 2004; 173(11): 6574 - 6582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Chen, X. Cui, G. D. Sempowski, C. Liu, and N. J. Chao Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease Blood, February 15, 2004; 103(4): 1534 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Kolb, C. Schmid, A. J. Barrett, and D. J. Schendel Graft-versus-leukemia reactions in allogeneic chimeras Blood, February 1, 2004; 103(3): 767 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. R. Godfrey, M. R. Krampf, P. A. Taylor, and B. R. Blazar Ex vivo depletion of alloreactive cells based on CFSE dye dilution, activation antigen selection, and dendritic cell stimulation Blood, February 1, 2004; 103(3): 1158 - 1165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Barrett, K. Rezvani, S. Solomon, A. M. Dickinson, X. N. Wang, G. Stark, H. Cullup, M. Jarvis, P. G. Middleton, and N. Chao New Developments in Allotransplant Immunology Hematology, January 1, 2003; 2003(1): 350 - 371. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
80%) of proliferative and lytic responses by activated
alloreactive T cells was subsequently achieved by incubating the mixed
lymphocyte culture with an agonistic monoclonal antibody to CD95, and
residual T cells recovered did not elicit alloreactivity upon challenge
to H-2d. Depletion of alloreactive T lymphocytes by AICD
was specific because reactivity to an I-Ad-restricted
ovalbumin (OVA) peptide by OVA-specific CD4+ T cells mixed
into the allogeneic T-cell pool and subjected to induction of
AICD in the absence of OVA peptide could be preserved. Adoptive
transfer of donor-derived allogeneic T lymphocytes, depleted from alloreactive T cells by AICD in vitro, in the parent (C3H/He) to
F1 (C3H/He × BALB/c) GvHD model prevented lethal
GvHD. The results presented suggest that alloreactive T cells can
effectively be depleted from allogeneic T cells by induction of AICD to
prevent GvHD and might introduce a new strategy for the separation of GvH-reactive T cells and T cells mediating antiviral and possibly graft-versus-leukemia effects.
(Blood. 2002;99:3041-3049)
-mercaptoethanol, 1%
antibiotic-antimycotic (Gibco) solution consisting of penicillin
(10 000 IU)/streptomycin (10 mg/mL)/amphotericin B (25 µg/mL), 1%
sodium bicarbonate, 1 mM/L sodium pyruvate, and 0.8% nonessential
amino acids, and maintained in flasks during culture.
Preparation of cell suspensions made from ex vivo-isolated cells was
conducted in Dulbecco modified Eagle medium (DMEM) (Biomed) containing
2% FCS or horse serum (Gibco) and 1% antibiotic-antimycotic (Gibco).
Culture medium for mixed lymphocyte reactions (MLC medium) consisted of
RPMI 1640 (Biomed) supplemented with 10% FCS (Gibco) and 5%
NCTC (Gibco) in addition to supplements used for cell
culture medium.
) or presence of 1 µg/mL (
) or 5 ng/mL (
) of
agonistic anti-CD95 mAb (Jo2), proliferation of T cells was determined
by 3H-thymidine uptake for the last 12 hours. Addition of a
1 µg/mL isotype-matched hamster-Ig control antibody (
) during
culture was performed as specificity control. Syngeneic controls (
)
are shown without induction of AICD. Results are expressed as mean
± SD of triplicate wells and depict 1 of at least 5 representative
experiments. (A) Proliferative response by allogeneic CD4+
responders. (B) Proliferative response by allogeneic CD8+
T cells.
), or with H-2d
stimulators presenting OVA peptide (
). In addition, remaining T-cell
responders from primary cultures were transferred into irradiated
F1 recipients. On day 6 after transfer, splenic responders
recovered from these recipients ex vivo (B) were tested for reactivity
to syngeneic spleen cells (
) or donor T lymphocytes depleted
of alloreactive responders by soluble anti-CD95 mAb (
immune regulation in a dynamic and unpredictable antigenic environment.
Annu Rev Immunol.
1999;17:221-253